Drive for generics sees Korea increasingly attractive to international pharma

31 Jul 2019

Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners.

Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.

Drive for generics sees Korea increasingly attractive to international pharma

In fact, South Korean President Moon Jae-in stated in May 2019 that the Government will help foster ‘the biotechnology and pharmaceutical sectors as the country's new economic growth drive’.

Emphasizing the shift in the country’s global reputation, provisional data from the CPhI Annual Report 2019 shows that Korea improved its scores across ‘API quality’, ‘growth potential’ and ‘innovation’, with ‘overall competitiveness’ rising by 9% in the last year.

The new findings are announced in the lead-up to CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – which will open its sixth edition at the Seoul COEX Convention and Exhibition Centre from 21-23 August 2019.

“The show is widely seen as a barometer of industry trends within the region and this year we expect to see an increase in international bio buyers looking for access to services, equipment and bio-solutions as well as domestic partners. In total, over 5000 attendees from more than 50 countries and more than 190 exhibitors will attend” commented Laura Murina, Brand Manager at Informa.

Korean pharmaceutical exports have become attractive due to competitive pricing in the generics market and, as a result, Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners. In fact, the Korea Trade-Investment Promotion Agency (KOTRA) is facilitating exhibitors to meet with overseas buyers selected by the Global Bio Pharma Plaza (GBPP) at the event.

Emphasizing the international nature of Korea’s growth in exports, the CPhI Korea Conference, an integral part of the event, will include sessions from the Thai FDA, the Japanese PMDA, the China Chamber of Commerce for Imports and Exports of Medicines and Health Products (CCCMHPIE), as well as the European Directorate for the Quality of Medicines. The agenda will include detailed analysis of international regulations, GMP, QbD, and comparative strategies for global market entry.

Murina, continued: “South Korea’s expanding generics market and changing regulations are driving more international companies towards local partnerships. One of the great added benefits of this event’s size and dynamics is that it allows attendees to have more in-depth and targeted meetings. The high quality of meetings means that they deliver a very high rate of partnership outcomes.”

Finally, to help international companies looking to enter the country, CPhI Korea is working with the Korea Pharmaceutical Traders Association (KPTA) to promote a Meet the Expert Programme, which is specifically designed to help international companies understand the complexities of the South Korean market.

Read More

Related news

One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
Industry on the brink of a new age of smart pharma manufacturing

Industry on the brink of a new age of smart pharma manufacturing

27 Sep 2019

Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.

Read more 
Huge boom in Korean Pharma reported at CPhI Korea

Huge boom in Korean Pharma reported at CPhI Korea

20 Sep 2019

Event sees new Memorandum of Understanding signed by PROLMED and KPTA.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

29 Aug 2019

Meet Avivia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more 
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

5 Aug 2019

Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Read more 
Huge CPhI & P-MEC China a direct result of surging manufacturing

Huge CPhI & P-MEC China a direct result of surging manufacturing

22 Jul 2019

Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more